1,651 Shares in Regeneron Pharmaceuticals, Inc. $REGN Purchased by Milestone Asset Management LLC

Milestone Asset Management LLC bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,651 shares of the biopharmaceutical company’s stock, valued at approximately $1,252,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in REGN. Arjuna Capital raised its position in Regeneron Pharmaceuticals by 3.2% in the first quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company’s stock worth $353,000 after acquiring an additional 14 shares during the period. Boyd Watterson Asset Management LLC OH grew its position in shares of Regeneron Pharmaceuticals by 1.4% during the 1st quarter. Boyd Watterson Asset Management LLC OH now owns 1,087 shares of the biopharmaceutical company’s stock valued at $840,000 after acquiring an additional 15 shares during the period. Geneos Wealth Management Inc. grew its position in shares of Regeneron Pharmaceuticals by 1.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 835 shares of the biopharmaceutical company’s stock valued at $645,000 after acquiring an additional 15 shares during the period. Aaron Wealth Advisors LLC grew its position in shares of Regeneron Pharmaceuticals by 1.5% during the 1st quarter. Aaron Wealth Advisors LLC now owns 1,102 shares of the biopharmaceutical company’s stock valued at $851,000 after acquiring an additional 16 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. increased its stake in shares of Regeneron Pharmaceuticals by 30.2% in the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 69 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 16 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $796.34 on Friday. The company has a market capitalization of $81.99 billion, a P/E ratio of 19.68, a P/E/G ratio of 1.35 and a beta of 0.16. Regeneron Pharmaceuticals, Inc. has a 1-year low of $564.00 and a 1-year high of $859.34. The firm’s 50 day simple moving average is $791.59 and its two-hundred day simple moving average is $721.30. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The business had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company’s revenue was up 16.7% on a year-over-year basis. During the same period in the prior year, the business posted $12.81 earnings per share. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 47.93 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were paid a dividend of $0.94 per share. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is 9.29%.

Insider Activity

In related news, EVP Marion Mccourt sold 1,215 shares of the company’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $1,032,750.00. Following the completion of the transaction, the executive vice president owned 13,134 shares of the company’s stock, valued at approximately $11,163,900. This represents a 8.47% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $340,000.00. Following the completion of the sale, the director owned 603 shares of the company’s stock, valued at $512,550. The trade was a 39.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 8,093 shares of company stock worth $6,506,845 in the last quarter. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: UBS upgraded Regeneron to “Buy” and raised its price target to $978 from $660, arguing that the market is underestimating the long-term opportunity for Dupixent. The new target implies substantial upside and is the clearest near-term catalyst for investor optimism. Tickerreport UBS upgrade article
• Positive Sentiment: A valuation analysis says Regeneron still appears below fair value after fresh trial data and renewed attention on its immunology alliance. The report suggests the company’s earnings power may not be fully reflected in its current valuation. Regeneron stock fair value article
• Positive Sentiment: Regeneron could benefit from having paid off its balance owed to Sanofi, which had reduced the revenue reported from their partnership. The change may improve the financial contribution from the collaboration going forward. Trefis Regeneron catalysts article
• Positive Sentiment: Analysts expect double-digit bottom-line growth in the upcoming third-quarter report, keeping earnings momentum and the company’s ability to exceed estimates in focus. Barchart Regeneron earnings preview
• Neutral Sentiment: A review of biotechnology-sector results included Regeneron among the companies investors are evaluating, but provided limited new company-specific information. Yahoo Finance biotechnology earnings review
• Negative Sentiment: Director Andrew Murphy sold 4,147 shares worth approximately $3.2 million under a pre-arranged Rule 10b5-1 plan. Because the sale was scheduled in advance, it is a limited bearish signal, although it may weigh modestly on sentiment.

Analysts Set New Price Targets

REGN has been the topic of a number of recent research reports. Guggenheim raised their target price on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Citigroup boosted their price target on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a “neutral” rating in a report on Monday, August 3rd. Jefferies Financial Group boosted their price target on Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Cantor Fitzgerald upped their price target on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Finally, Leerink Partners raised their price objective on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a “market perform” rating in a research note on Monday, August 17th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $845.21.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.